Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 39,395 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

39,395 Papers indexed
1,440 Papers AI scored
39,395 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

39395 results
B
AI -
Standard 75.6
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 38.0; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

B
[Efficacy analysis of tumor necrosis factor inhibitors in the treatment of chronic recurrent multifocal osteomyelitis].
PMID 41991296 Published: 2026-04-06 Ingested: 2026-08-02 12:06 AM Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
AI -
Standard 75.6
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 63.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 75.6
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 58.0; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
Living beyond cancer in childhood and adolescence: A systematic review.
PMID 41619380 Published: 2026-01-30 Ingested: 2026-08-02 12:06 AM Journal of pediatric nursing
AI -
Standard 75.6
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 38.0; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Standard 75.6
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 33.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
[Identify the factors associated with treatment-free remission outcomes after imatinib discontinuation in children and adolescent patients with chronic myeloid leukemia].
PMID 41145282 Published: 2025-09-14 Ingested: 2026-08-02 12:05 AM Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
AI -
Standard 75.6
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 63.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 75.6
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 53.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
Primary Epstein-Barr virus infection in preadolescent children: A prospective study.
PMID 40934748 Published: 2025-08-31 Ingested: 2026-08-02 12:04 AM Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
AI -
Standard 75.6
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 28.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
Phase 1 and expanded imaging study of tozuleristide in patients with pediatric primary central nervous system tumors.
PMID 40882241 Published: 2025-08-29 Ingested: 2026-08-02 12:04 AM Journal of neurosurgery. Pediatrics
AI -
Standard 75.6
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 28.0; sample size: 30.0; recency: 100.0; abstract quality: 100.0.

Previous
Page 362 of 3283
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic